RxDoctor Payments Data

Scott Westphal, MD

Nephrology · Omaha, NENPI 1093031981

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Eurofins Viracor, LLC at 37.8% of the total. Reporting peaked in 2019 at $370 and has fallen 89.4% since, to $39 in 2025. That places this record below the midpoint for nephrology clinicians in NE, where the typical reported total is $1,214.

$746in general payments, 2019–2025

Across 6 payments — averaging $124.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eurofins Viracor, LLC$282
  • Sanofi$248
  • E.r. Squibb & Sons, L.L.C.$122
  • Sanofi-aventis U.S. LLC$95
$267,748in research payments, 2019–2025

Across 31 payments — averaging $8637.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$268K

What the payments were for

  • Food & beverage$746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eurofins Viracor, LLC2$282
Sanofi2$248
E.r. Squibb & Sons, L.L.C.1$122
Sanofi-aventis U.S. LLC1$95

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746 in reported general payments places this provider in the 40th percentile of 60 nephrology providers in Nebraska.

See all nephrology providers in Nebraska

Medicare billing

Part B allowed, 2024
$32,203
Medicare patients
131
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$10,472
Cinacalcet Hcl39$5,369
Valganciclovir Hcl22$5,006
Mycophenolic AcidMycophenolate Sodium19$4,994
Tacrolimus29$4,147
Nifedipine ErNifedipine126$3,007
Prednisone317$1,975
Dexlansoprazole DrDexlansoprazole13$1,778
Carvedilol171$1,376
Fludrocortisone Acetate18$837
Famotidine47$831
Potassium Chloride25$786
Pantoprazole Sodium72$759
Metoprolol Succinate37$675
Valsartan17$649

Paid to pharmacies, not to this prescriber.

Other nephrology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →